{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:24:54Z","timestamp":1761017094227},"reference-count":48,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2015]]},"DOI":"10.5551\/jat.26856","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T15:12:51Z","timestamp":1427901171000},"page":"796-815","source":"Crossref","is-referenced-by-count":13,"title":["Association between <i>SLCO1B1 521 T<\/i>\uff1e<i>C<\/i> and <i>388 A<\/i>\uff1e<i>G <\/i>Polymorphisms and Statins Effectiveness: A Meta-Analysis"],"prefix":"10.5551","volume":"22","author":[{"given":"Rong","family":"Dai","sequence":"first","affiliation":[{"name":"School of Public Health and Management, Research Center for Medicine and Social Development, The Innovation Center for Social Risk Government in Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[{"name":"School of Public Health and Management, Research Center for Medicine and Social Development, The Innovation Center for Social Risk Government in Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Public Health and Management, Research Center for Medicine and Social Development, The Innovation Center for Social Risk Government in Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The First Affiliated Hospital of Chongqing Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changkai","family":"Deng","sequence":"additional","affiliation":[{"name":"Chengdu Women's and Children's Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Tang","sequence":"additional","affiliation":[{"name":"School of Public Health and Management, Research Center for Medicine and Social Development, The Innovation Center for Social Risk Government in Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Public Health and Management, Research Center for Medicine and Social Development, The Innovation Center for Social Risk Government in Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Public Health and Management, Research Center for Medicine and Social Development, The Innovation Center for Social Risk Government in Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Public Health and Management, Research Center for Medicine and Social Development, The Innovation Center for Social Risk Government in Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet, 1997; 349: 1436-1442","DOI":"10.1016\/S0140-6736(96)07495-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. Atheroscler Suppl, 2004; 5: 91-97","DOI":"10.1016\/j.atherosclerosissup.2004.08.029"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI, et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation, 1995; 91: 2528-2540","DOI":"10.1161\/01.CIR.91.10.2528"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335: 1001-1009","DOI":"10.1056\/NEJM199610033351401"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998; 339: 1349-1357","DOI":"10.1056\/NEJM199811053391902"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J Atheroscler Thromb, 2000; 7: 110-121","DOI":"10.5551\/jat1994.7.110"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl, 2004; 5: 81-87","DOI":"10.1016\/j.atherosclerosissup.2004.08.027"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto KItakura H: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J, 2002; 66: 1087-1095","DOI":"10.1253\/circj.66.1087"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J, 2002; 66: 1096-1100","DOI":"10.1253\/circj.66.1096"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Matsuzawa Y, Kita T, Mabuchi H, Matsuzaki M, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H: Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J, 2003; 67: 287-294","DOI":"10.1253\/circj.67.287"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med, 1999; 341: 70-76","DOI":"10.1056\/NEJM199907083410202"},{"key":"12","unstructured":"12) Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien EOstergren J: Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens, 2001; 19: 1139-1147"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kim RB: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about? Clin Pharmacol Ther, 2004; 75: 381-385","DOI":"10.1016\/j.clpt.2004.01.004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ: Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther, 2005; 78: 342-350","DOI":"10.1016\/j.clpt.2005.07.003"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Lau YY, Okochi H, Huang Y, Benet LZ: Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther, 2006; 316: 762-771","DOI":"10.1124\/jpet.105.093088"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem, 2001; 276: 35669-35675","DOI":"10.1074\/jbc.M103792200"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther, 2003; 73: 554-565","DOI":"10.1016\/S0009-9236(03)00060-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivisto KT: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics, 2004; 14: 429-440","DOI":"10.1097\/01.fpc.0000114750.08559.32"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Akao H, Polisecki E, Kajinami K, Trompet S, Robertson M, Ford I, Jukema JW, de Craen AJ, Westendorp RG, Shepherd J, Packard C, Buckley BM, Schaefer EJ: Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis, 2012; 220: 413-417","DOI":"10.1016\/j.atherosclerosis.2011.09.028"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T: Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet, 2004; 19: 375-380","DOI":"10.2133\/dmpk.19.375"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Zhang W, Chen BL, Ozdemir V, He YJ, Zhou G, Peng DD, Deng S, Xie QY, Xie W, Xu LY, Wang LC, Fan L, Wang A, Zhou HH: SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol, 2007; 64: 346-352","DOI":"10.1111\/j.1365-2125.2007.02892.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, Bruckert E, Carrie A: Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics, 2008; 9: 1217-1227","DOI":"10.2217\/14622416.9.9.1217"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Martin NG, Li KW, Murray H, Putt W, Packard CJ, Humphries SE: The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. Br J Clin Pharmacol, 2012; 73: 303-306","DOI":"10.1111\/j.1365-2125.2011.04090.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Yang GP, Yuan H, Tang B, Zhang W, Wang LS, Huang ZJ, Ou-Yang DS, Zhang GX, Zhou HH: Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. Acta Pharmacol Sin, 2010; 31: 382-386","DOI":"10.1038\/aps.2009.203"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Fu Q, Li YP, Gao Y, Yang SH, Lu PQ, Jia M, Zhang LR: Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur J Clin Pharmacol, 2013; 69: 1269-1274","DOI":"10.1007\/s00228-012-1453-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hu M, Mak VW, Tomlinson B: Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics, 2012; 22: 803-806","DOI":"10.1097\/FPC.0b013e3283557c98"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, Banerjee P, Milos PM, Myrand SP, Paulauskis J, Milad MA, Sasiela WJ: An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J, 2005; 5: 352-358","DOI":"10.1038\/sj.tpj.6500328"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hedman M, Antikainen M, Holmberg C, Neuvonen M, Eichelbaum M, Kivisto KT, Neuvonen PJ, Niemi M: Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol, 2006; 61: 706-715","DOI":"10.1111\/j.1365-2125.2006.02643.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Rodrigues AC, Perin PM, Purim SG, Silbiger VN, Genvigir FD, Willrich MA, Arazi SS, Luchessi AD, Hirata MH, Bernik MM, Dorea EL, Santos C, Faludi AA, Bertolami MC, Salas A, Freire A, Lareu MV, Phillips C, Porras-Hurtado L, Fondevila M, Carracedo A, Hirata RD: Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response. Int J Mol Sci, 2011; 12: 5815-5827","DOI":"10.3390\/ijms12095815"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Sortica VA, Fiegenbaum M, Lima LO, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH: SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians. Clin Chem Lab Med, 2012; 50: 441-448","DOI":"10.1515\/cclm.2011.804"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Shabana MF, Mishriki AA, Issac MS, Bakhoum SW: Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Mol Diagn Ther, 2013; 17: 299-309","DOI":"10.1007\/s40291-013-0038-3"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Ghatak A, Faheem O, Thompson PD: The genetics of statin-induced myopathy. Atherosclerosis, 2010; 210: 337-343","DOI":"10.1016\/j.atherosclerosis.2009.11.033"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Collins R: SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med, 2008; 359: 789-799","DOI":"10.1056\/NEJMoa0801936"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Linde R, Peng L, Desai M, Feldman D: The role of vitamin D and SLCO1B1* 5 gene polymorphism in statinassociated myalgias. Dermatoendocrinol, 2010; 2: 77","DOI":"10.4161\/derm.2.2.13509"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, Pirmohamed M: SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther, 2013; 94: 695-701","DOI":"10.1038\/clpt.2013.161"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS: The SLCO1B1* 5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol, 2009; 54: 1609-1616","DOI":"10.1016\/j.jacc.2009.04.053"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Kim RB: Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants. Pharmacogenet Genomics, 2007; 17: 647-656","DOI":"10.1097\/FPC.0b013e3280ef698f"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J: Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg, 2003; 73: 712-716","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Chowbay B, Li H, David M, Cheung YB, Lee EJ: Metaanalysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol, 2005; 60: 159-171","DOI":"10.1111\/j.1365-2125.2005.02392.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol, 2009; 169: 505-514","DOI":"10.1093\/aje\/kwn359"},{"key":"41","unstructured":"41) Hubacek JA, Dlouha D, Adamkova V, Lanska V, Ceska R, Vrablik M: Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. Neuro Endocrinol Lett, 2012; 33 Suppl 2: 22-25"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT: Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther, 2006; 79: 419-426","DOI":"10.1016\/j.clpt.2006.01.010"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Hopewell JC, Parish S, Offer A, Link E, Clarke R, Lathrop M, Armitage J, Collins R: Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J, 2013; 34: 982-992","DOI":"10.1093\/eurheartj\/ehs344"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM: Genetic determinants of statininduced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet, 2012; 5: 257-264","DOI":"10.1161\/CIRCGENETICS.111.961144"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Singer JB, Holdaas H, Jardine AG, Fellstrom B, Os I, Bermann G, Meyer JM: Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res, 2007; 48: 2072-2078","DOI":"10.1194\/jlr.M700076-JLR200"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Pasanen MK, Miettinen TA, Gylling H, Neuvonen PJ, Niemi M: Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics, 2008; 18: 921-926","DOI":"10.1097\/FPC.0b013e32830c1b5f"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Patel J, Abd T, Blumenthal RS, Nasir K, Superko HR: Genetics and personalized medicine--a role in statin therapy? Curr Atheroscler Rep, 2014; 16: 384","DOI":"10.1007\/s11883-013-0384-y"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, Brescia D: Pharmacokinetics and pharmaco ynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther, 1990; 48: 201-207","DOI":"10.1038\/clpt.1990.136"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/22\/8\/22_26856\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T18:46:37Z","timestamp":1566499597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/22\/8\/22_26856\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.26856","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}